Prevalence and distribution of non-typhoidal Salmonella enterica serogroups and serovars isolated from normally sterile sites: a global systematic review

Nienke N. Hagedoorn; Shruti Murthy; Megan Birkhold; Christian S. Marchello; John A. Crump; Vacc-iNTS Consortium

doi:10.1101/2023.06.13.23291315

Summary

To inform vaccine development strategies, we aimed to systematically review evidence on the prevalence and distribution of non-typhoidal Salmonella enterica serogroups and serovars. We searched four databases from inception through 4 June 2021. We included articles that reported at least one non-typhoidal Salmonella enterica strain by serogroup or serovar isolated from a normally sterile site. Of serogrouped isolates, we pooled the prevalence of serogroup O:4, serogroup O:9, and other serogroups using random-effects meta-analyses. Of serotyped isolates, we pooled the prevalence of Salmonella Typhimurium (member of serogroup O:4), Salmonella Enteritidis (member of serogroup O:9), and other serovars. Of 82 studies yielding 24,258 serogrouped isolates, pooled prevalence (95% CI) was 44.7% (36.3%-48.3%) for serogroup O:4, 45.4% (36.9%-49.0%) for serogroup O:9, and 9.9% (6.1%-13.3%) for other serogroups. Pooled prevalence (95%CI) was 36.8% (29.9%-44.0%) for Salmonella Typhimurium, 37.8% (33.2%-42.4%) for Salmonella Enteritidis, and 18.4% (11.4%-22.9%) for other serovars. Of global serogrouped non-typhoidal Salmonella isolates from normally sterile sites, serogroup O:4 and O:9 together accounted for 90%. Of global serotyped isolates, serovars Typhimurium and Enteritidis together accounted for 75%. Vaccine development strategies covering serogroups O:4 and O:9, or serovars Typhimurium and Enteritidis, have the potential to prevent the majority of non-typhoidal Salmonella invasive disease.

PROSPERO:CRD42022376658.

Key results

Invasive infections in normally sterile sites caused by non-typhoidal Salmonella have a case fatality ratio of 15%.
Vaccine products for human non-typhoidal Salmonella are in currently in development.
For future vaccine strategies, we provide global non-typhoidal Salmonella serogroup and serovar coverage by region and by age groups.
Serogroups O:4 and O:9 account for 90% of isolates of non-typhoidal Salmonella enterica from normally sterile sites.
Serovars Typhimurium and Enteritidis, members of serogroup O:4 and O:9, respectively, cover 75% of isolates of non-typhoidal Salmonella enterica from normally sterile sites.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=376658

Funding Statement

This project has received funding from the EU Horizon 2020 research and innovation programme under the project Vacc-iNTS (grant agreement number 815439).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Nienke N. Hagedoorn – Nienke.hagedoorn{at}otago.ac.nz, Shruti Murthy – shruti.murthy{at}otago.ac.nz, Megan Birkhold – MBirkhold{at}som.umaryland.edu, Christian S. Marchello - Christian.Marchello{at}health.govt.nz, John A. Crump: john.crump{at}otago.ac.nz

Data Availability

Data underlying this study will be made available upon acceptance of publication in a repository.

Abbreviations

GMMA: Generalized Modules for Membrane Antigens
NTS: non-typhoidal Salmonella
PROSPERO: Prospective Register of Systematic Reviews
UN: United Nations

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.